RxDoctor Payments Data

Raquel Bernal, APRN

Nurse Practitioner · Miami, FLNPI 1770058109

Payments from drug & device makers

$3,177in general payments, 2019–2025

Across 137 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$563
  • E.r. Squibb & Sons, L.L.C.$302
  • Pfizer$240
  • Johnson & Johnson$236
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$201
  • Amgen$192
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,177 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$3,330
Medicare patients
26
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$98,557
OzempicSemaglutide78$74,169
MounjaroTirzepatide50$50,521
XareltoRivaroxaban31$42,653
EntrestoSacubitril/Valsartan30$42,151
BrilintaTicagrelor18$18,450
FarxigaDapagliflozin Propanediol14$15,407
WegovySemaglutide11$14,365
VascepaIcosapent Ethyl19$10,953
Metoprolol Succinate152$2,109
Losartan Potassium143$1,666
Atorvastatin Calcium166$1,621
Rosuvastatin Calcium118$1,517
ClopidogrelClopidogrel Bisulfate90$999
Amlodipine Besylate129$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$240$98,55790 claims
Novo NordiskOzempic, Wegovy$563$88,53489 claims
Lilly USA, LLCMounjaro$98$50,52150 claims
Johnson & JohnsonXarelto$236$42,65331 claims
NovartisEntresto$180$42,15130 claims
AstraZenecaBrilinta, Farxiga$175$33,85732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →